Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics Inc. (Nasdaq: CMPX) advances novel antibody therapies targeting cancer's complex biology through its clinical-stage pipeline. This dedicated news center provides investors and researchers with essential updates on oncology developments, trial milestones, and scientific breakthroughs.
Access timely reports on bispecific antibody programs, including Tovecimig (CTX-009) for biliary tract cancers and CTX-471's CD137 agonist mechanism. Track regulatory progress across multiple indications and discover partnership announcements leveraging Compass' StitchMabs platform technology.
Our curated news collection serves as your primary source for:
- Phase 1-3 clinical trial updates
- FDA submissions and international regulatory milestones
- Peer-reviewed research publications
- Strategic collaborations in immuno-oncology
Bookmark this page for real-time insights into Compass' work on angiogenesis modulation and tumor microenvironment targeting. Monitor biomarker-driven developments that could shape next-generation cancer treatments.
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced its participation in the H.C. Wainwright BioConnect Investor Conference in New York City on May 2, 2023. The event will feature a Fireside Chat scheduled for 10 AM ET. A webcast link for the presentation is available online. Following the live event, a replay will be archived for 90 days on Compass's Events page. Compass Therapeutics is focused on developing proprietary antibody-based therapeutics targeting oncology, aiming to engage multiple critical biological pathways for effective anti-tumor responses. Founded in 2014 and based in Boston, the company is dedicated to advancing its clinical pipeline with novel product candidates.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
